Technical Analysis for BLUE - bluebird bio, Inc.

Grade Last Price % Change Price Change
grade D 122.86 1.18% 1.43
BLUE closed up 1.18 percent on Friday, May 24, 2019, on 65 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BLUE trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness 1.18%
Slingshot Bearish Bearish Swing Setup -1.72%
Oversold Stochastic Weakness -1.72%
Stochastic Reached Oversold Weakness -1.92%
Oversold Stochastic Weakness -1.92%
NR7 Range Contraction -4.27%
Multiple of Ten Bearish Other -4.27%

Older signals for BLUE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology New Jersey Rare Diseases Medical Genetics Celgene Genetic Genealogy Human Diseases Summit
Is BLUE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 199.7
52 Week Low 87.49
Average Volume 452,695
200-Day Moving Average 134.6883
50-Day Moving Average 143.682
20-Day Moving Average 132.1235
10-Day Moving Average 125.117
Average True Range 5.9782
ADX 35.66
+DI 9.2576
-DI 25.5145
Chandelier Exit (Long, 3 ATRs ) 129.5454
Chandelier Exit (Short, 3 ATRs ) 138.0946
Upper Bollinger Band 148.1114
Lower Bollinger Band 116.1356
Percent B (%b) 0.21
BandWidth 24.201448
MACD Line -5.875
MACD Signal Line -5.3792
MACD Histogram -0.4958
Fundamentals Value
Market Cap 5.6 Billion
Num Shares 45.6 Million
EPS -7.33
Price-to-Earnings (P/E) Ratio -16.76
Price-to-Sales 233.66
Price-to-Book 5.18
PEG Ratio 0.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 127.42
Resistance 3 (R3) 127.43 125.92 126.66
Resistance 2 (R2) 125.92 124.76 125.92 126.41
Resistance 1 (R1) 124.39 124.04 125.16 124.38 126.15
Pivot Point 122.88 122.88 123.26 122.88 122.88
Support 1 (S1) 121.35 121.72 122.12 121.34 119.57
Support 2 (S2) 119.84 121.00 119.84 119.31
Support 3 (S3) 118.31 119.84 119.06
Support 4 (S4) 118.30